BioMarin Pharmaceutical revenue and financials
$56.22Change from previous close: −2.29%Absolute change: −$1.32
In the fiscal year ended December 2025, BioMarin Pharmaceutical reported revenue of $3.22B (+12.87% year over year). Net income was $348.9M, a net margin of 10.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.87%
- 2025 vs 2024
- Net income growth
- −18.26%
- 2025 vs 2024
- Net margin
- 10.8%
- 2024: 15.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11,723 | 8,591 | 7,594 | 7,615 | 7,456 | 7,147 | 6,989 | 6,851 | 7,067 | 6,873 | 6,842 | 6,758 |
| Current assets | 3,972 | 4,605 | 3,953 | 3,855 | 3,805 | 3,468 | 3,232 | 3,057 | 3,260 | 2,985 | 2,956 | 2,955 |
| Cash and equivalents | 874 | 2,222 | 1,312 | 1,250 | 1,214 | 1,049 | 943 | 675 | 972 | 747 | 755 | 785 |
| Short-term investments | 0.0 | 0.0 | 249 | 228 | 218 | 224 | 195 | 255 | 252 | 300 | 319 | 340 |
| Receivables | 1,061 | 904 | 908 | 790 | 856 | 739 | 661 | 778 | 691 | 637 | 634 | 572 |
| Inventory | 1,783 | 1,273 | 1,299 | 1,382 | 1,340 | 1,275 | 1,233 | 1,179 | 1,184 | 1,138 | 1,107 | 1,032 |
| Net property, plant and equipment | 990 | 958 | 992 | 1,038 | 1,030 | 1,033 | 1,077 | 1,045 | 1,053 | 1,060 | 1,112 | 1,067 |
| Goodwill | 656 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 |
| Other intangible assets | 4,879 | 205 | 311 | 233 | 240 | 247 | 321 | 261 | 266 | 280 | 325 | 302 |
| Long-term investments | 0.0 | 0.0 | 492 | 513 | 509 | 507 | 521 | 569 | 564 | 632 | 622 | 559 |
| Current liabilities | 1,664 | 793 | 759 | 798 | 684 | 628 | 607 | 716 | 1,067 | 1,088 | 1,177 | 1,163 |
| Accounts payable | 407 | 395 | 313 | 390 | 311 | 294 | 235 | 312 | 257 | 292 | 316 | 301 |
| Long-term debt | 3,528 | 1,430 | 597 | 597 | 596 | 596 | 595 | 595 | 594 | 594 | 593 | 593 |
| Total debt | 4,202 | 1,440 | 606 | 604 | 604 | — | — | — | — | — | — | — |
| Total liabilities | 5,402 | 2,379 | 1,507 | 1,558 | 1,429 | 1,354 | 1,331 | 1,438 | 1,781 | 1,799 | 1,890 | 1,861 |
| Total equity (incl. minority) | 6,322 | 6,212 | 6,087 | 6,057 | 6,027 | 5,793 | 5,658 | 5,413 | 5,286 | 5,074 | 4,952 | 4,897 |
| Retained earnings | 304 | 260 | 154 | 201 | 232 | -9.0 | -195 | -320 | -426 | -533 | -622 | -642 |